Deprecated: Function get_magic_quotes_gpc() is deprecated in /home/uchis2/domains/uchisearch.com/public_html/category.php on line 152

Notice: Undefined property: stdClass::$live in /home/uchis2/domains/uchisearch.com/public_html/category.php on line 469

Notice: Undefined property: stdClass::$live in /home/uchis2/domains/uchisearch.com/public_html/category.php on line 474

Notice: Undefined variable: type in /home/uchis2/domains/uchisearch.com/public_html/category.php on line 560

Notice: Undefined variable: sortString in /home/uchis2/domains/uchisearch.com/public_html/category.php on line 563
PROCESSING REACTIVATION

PROCESSING REACTIVATION

Brand Owner Address Description
DONAU CARBON Donau Carbon GmbH Gwinnerstr. 27-33 Frankfurt am Main 60388 Germany Processing and reactivation in the nature of regeneration of highly porous, amorphous carbon, in particular, activated carbon;The mark consists of the wording DONAU CARBON in capital letters to the right of a square containing the mirror image of two semi-circles that touch in the middle. The empty space above and below where the two semi-circles meet is shaded.;Color is not claimed as a feature of the mark.;Chemicals used in industry, in particular activated carbon;The English translation of DONAU in the mark is Danube.;CARBON;
 

Where the owner name is not linked, that owner no longer owns the brand

   
Technical Examples
  1. Data consistent with autoimmune disease being caused by Epstein-Barr virus are shown. Based on this evidence, an effective vaccine would prevent the autoimmune disease in those vaccinated, modified or administered so that the vaccine is not itself capable of inducing autoimmune disease. In the case of anti-Sm, structures to be avoided in an Epstein-Barr virus-derived vaccine have been identified. Differences have been identified in the immune responses to Epstein-Barr infection between individuals who develop a specific autoimmune disease and those who do not. These differences are used to distinguish those who are at greater risk for developing specific autoimmune diseases from those who are a lesser risk. Assuming Epstein-Barr virus causes autoimmune disease and that Epstein-Barr virus remains latent in the patient for life, reactivation of the virus from the latent state is important in generating or maintaining the autoimmune response that culminates in autoimmune disease. Cells infected with latent virus may also encourage autoimmunity. Based on the understanding that reactivation or latency are important to produce or sustain autoimmunity, then therapies directed against Epstein-Barr virus will also be effective therapies for the autoimmune manifestations of disease for which Epstein-Barr virus is responsible.